© exalt
Austria
exalt
- 2026
- Speaker
- Venture
exalt® develops fScreen, a functional diagnostic platform that identifies the most effective cancer treatment for each patient within 72 hours — by directly testing tumor cells against 140+ approved drugs. Validated in two prospective clinical trials, including a Roche-funded randomized study, fScreen launches in 2027 with Europe's leading leukemia laboratory.